Bromo-PEG1-C2-azide
CAS No. 1144106-65-9
Bromo-PEG1-C2-azide ( —— )
Catalog No. M26932 CAS No. 1144106-65-9
Bromo-PEG1-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 61 | Get Quote |
|
10MG | 87 | Get Quote |
|
25MG | 143 | Get Quote |
|
50MG | 210 | Get Quote |
|
100MG | 300 | Get Quote |
|
200MG | 447 | Get Quote |
|
500MG | 732 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBromo-PEG1-C2-azide
-
NoteResearch use only, not for human use.
-
Brief DescriptionBromo-PEG1-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
DescriptionBromo-PEG1-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHuman Endogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1144106-65-9
-
Formula Weight194.0
-
Molecular FormulaC4H8BrN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESBrCCOCCN=[N+]=[N-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Seiler N, et al. The influence of catabolic reactions on polyamine excretion. Biochem J. 1985 Jan 1;225(1):219-26.
molnova catalog
related products
-
A-7 hydrochloride
calmodulin antagonist
-
Pratol
Pratol significantly increased melanin content and tyrosinase activity in the cells without being cytotoxic.
-
Tocofersolan
Tocofersolan is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of Tocopherol. Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis.